Daytime sleepiness associated with lurasidone and quetiapine XR: Results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia

Antony D. Loebel, Cynthia O. Siu, Josephine B. Cucchiaro, Andrei A. Pikalov, Philip D Harvey

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective The aim of this analysis was to compare the effects of 2 atypical antipsychotic agents, lurasidone (80 mg/d or 160 mg/d) and quetiapine XR (600 mg/d), on daytime alertness, and to evaluate the effects of daytime sleepiness on treatment outcomes in patients with an acute exacerbation of schizophrenia. Methods Patients who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) criteria for schizophrenia were randomized to 6 weeks of double-blind treatment with fixed doses of lurasidone 80 mg/d (n = 125), lurasidone 160 mg/d (n = 121), quetiapine XR 600 mg/d (n = 119), or placebo (n = 121), all dosed once daily in the evening, with food. Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS). Results Daytime sleepiness improved in the lurasidone and placebo-treated groups but worsened in the quetiapine XR treatment group when compared to placebo (p = 0.001) and to either dose of lurasidone (both p < 0.01). Sedation associated with quetiapine XR treatment mediated an improvement in agitation [assessed by the Positive and Negative Syndrome Scale - Excitement (PANSS-EC) subscale] and a worsening in functional capacity [assessed by the University of California-San Diego (UCSD) Performance-Based Skills Assessment - Brief Version (UPSA-B) total score]; these mediating relationships were not observed for the lurasidone or placebo treatment groups. Conclusion In this 6-week double-blind study, treatment with lurasidone 80 mg or 160 mg, administered once daily in the evening, was associated with a reduction in daytime sleepiness similar in magnitude to placebo, while quetiapine XR 600 mg/d was associated with a significant increase in daytime sleepiness, compared to both lurasidone dose groups and placebo. Daytime sleepiness was associated with improvement in agitation and worsening in functional capacity for quetiapine XR, but not lurasidone or placebo-treated patients.

Original languageEnglish
Pages (from-to)197-205
Number of pages9
JournalCNS Spectrums
Volume19
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Schizophrenia
Placebos
Diagnostic and Statistical Manual of Mental Disorders
Therapeutics
Lurasidone Hydrochloride
Quetiapine Fumarate
Double-Blind Method
Antipsychotic Agents
Food

Keywords

  • Atypical antipsychotics
  • daytime sleepiness
  • Epworth Sleepiness Scale
  • lurasidone
  • schizophrenia.

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Daytime sleepiness associated with lurasidone and quetiapine XR : Results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. / Loebel, Antony D.; Siu, Cynthia O.; Cucchiaro, Josephine B.; Pikalov, Andrei A.; Harvey, Philip D.

In: CNS Spectrums, Vol. 19, No. 2, 01.01.2014, p. 197-205.

Research output: Contribution to journalArticle

Loebel, Antony D. ; Siu, Cynthia O. ; Cucchiaro, Josephine B. ; Pikalov, Andrei A. ; Harvey, Philip D. / Daytime sleepiness associated with lurasidone and quetiapine XR : Results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. In: CNS Spectrums. 2014 ; Vol. 19, No. 2. pp. 197-205.
@article{29762e1a81824776a307b075c630e134,
title = "Daytime sleepiness associated with lurasidone and quetiapine XR: Results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia",
abstract = "Objective The aim of this analysis was to compare the effects of 2 atypical antipsychotic agents, lurasidone (80 mg/d or 160 mg/d) and quetiapine XR (600 mg/d), on daytime alertness, and to evaluate the effects of daytime sleepiness on treatment outcomes in patients with an acute exacerbation of schizophrenia. Methods Patients who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) criteria for schizophrenia were randomized to 6 weeks of double-blind treatment with fixed doses of lurasidone 80 mg/d (n = 125), lurasidone 160 mg/d (n = 121), quetiapine XR 600 mg/d (n = 119), or placebo (n = 121), all dosed once daily in the evening, with food. Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS). Results Daytime sleepiness improved in the lurasidone and placebo-treated groups but worsened in the quetiapine XR treatment group when compared to placebo (p = 0.001) and to either dose of lurasidone (both p < 0.01). Sedation associated with quetiapine XR treatment mediated an improvement in agitation [assessed by the Positive and Negative Syndrome Scale - Excitement (PANSS-EC) subscale] and a worsening in functional capacity [assessed by the University of California-San Diego (UCSD) Performance-Based Skills Assessment - Brief Version (UPSA-B) total score]; these mediating relationships were not observed for the lurasidone or placebo treatment groups. Conclusion In this 6-week double-blind study, treatment with lurasidone 80 mg or 160 mg, administered once daily in the evening, was associated with a reduction in daytime sleepiness similar in magnitude to placebo, while quetiapine XR 600 mg/d was associated with a significant increase in daytime sleepiness, compared to both lurasidone dose groups and placebo. Daytime sleepiness was associated with improvement in agitation and worsening in functional capacity for quetiapine XR, but not lurasidone or placebo-treated patients.",
keywords = "Atypical antipsychotics, daytime sleepiness, Epworth Sleepiness Scale, lurasidone, schizophrenia.",
author = "Loebel, {Antony D.} and Siu, {Cynthia O.} and Cucchiaro, {Josephine B.} and Pikalov, {Andrei A.} and Harvey, {Philip D}",
year = "2014",
month = "1",
day = "1",
doi = "10.1017/S1092852913000904",
language = "English",
volume = "19",
pages = "197--205",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "2",

}

TY - JOUR

T1 - Daytime sleepiness associated with lurasidone and quetiapine XR

T2 - Results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia

AU - Loebel, Antony D.

AU - Siu, Cynthia O.

AU - Cucchiaro, Josephine B.

AU - Pikalov, Andrei A.

AU - Harvey, Philip D

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective The aim of this analysis was to compare the effects of 2 atypical antipsychotic agents, lurasidone (80 mg/d or 160 mg/d) and quetiapine XR (600 mg/d), on daytime alertness, and to evaluate the effects of daytime sleepiness on treatment outcomes in patients with an acute exacerbation of schizophrenia. Methods Patients who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) criteria for schizophrenia were randomized to 6 weeks of double-blind treatment with fixed doses of lurasidone 80 mg/d (n = 125), lurasidone 160 mg/d (n = 121), quetiapine XR 600 mg/d (n = 119), or placebo (n = 121), all dosed once daily in the evening, with food. Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS). Results Daytime sleepiness improved in the lurasidone and placebo-treated groups but worsened in the quetiapine XR treatment group when compared to placebo (p = 0.001) and to either dose of lurasidone (both p < 0.01). Sedation associated with quetiapine XR treatment mediated an improvement in agitation [assessed by the Positive and Negative Syndrome Scale - Excitement (PANSS-EC) subscale] and a worsening in functional capacity [assessed by the University of California-San Diego (UCSD) Performance-Based Skills Assessment - Brief Version (UPSA-B) total score]; these mediating relationships were not observed for the lurasidone or placebo treatment groups. Conclusion In this 6-week double-blind study, treatment with lurasidone 80 mg or 160 mg, administered once daily in the evening, was associated with a reduction in daytime sleepiness similar in magnitude to placebo, while quetiapine XR 600 mg/d was associated with a significant increase in daytime sleepiness, compared to both lurasidone dose groups and placebo. Daytime sleepiness was associated with improvement in agitation and worsening in functional capacity for quetiapine XR, but not lurasidone or placebo-treated patients.

AB - Objective The aim of this analysis was to compare the effects of 2 atypical antipsychotic agents, lurasidone (80 mg/d or 160 mg/d) and quetiapine XR (600 mg/d), on daytime alertness, and to evaluate the effects of daytime sleepiness on treatment outcomes in patients with an acute exacerbation of schizophrenia. Methods Patients who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) criteria for schizophrenia were randomized to 6 weeks of double-blind treatment with fixed doses of lurasidone 80 mg/d (n = 125), lurasidone 160 mg/d (n = 121), quetiapine XR 600 mg/d (n = 119), or placebo (n = 121), all dosed once daily in the evening, with food. Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS). Results Daytime sleepiness improved in the lurasidone and placebo-treated groups but worsened in the quetiapine XR treatment group when compared to placebo (p = 0.001) and to either dose of lurasidone (both p < 0.01). Sedation associated with quetiapine XR treatment mediated an improvement in agitation [assessed by the Positive and Negative Syndrome Scale - Excitement (PANSS-EC) subscale] and a worsening in functional capacity [assessed by the University of California-San Diego (UCSD) Performance-Based Skills Assessment - Brief Version (UPSA-B) total score]; these mediating relationships were not observed for the lurasidone or placebo treatment groups. Conclusion In this 6-week double-blind study, treatment with lurasidone 80 mg or 160 mg, administered once daily in the evening, was associated with a reduction in daytime sleepiness similar in magnitude to placebo, while quetiapine XR 600 mg/d was associated with a significant increase in daytime sleepiness, compared to both lurasidone dose groups and placebo. Daytime sleepiness was associated with improvement in agitation and worsening in functional capacity for quetiapine XR, but not lurasidone or placebo-treated patients.

KW - Atypical antipsychotics

KW - daytime sleepiness

KW - Epworth Sleepiness Scale

KW - lurasidone

KW - schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=84901713564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901713564&partnerID=8YFLogxK

U2 - 10.1017/S1092852913000904

DO - 10.1017/S1092852913000904

M3 - Article

C2 - 24330860

AN - SCOPUS:84901713564

VL - 19

SP - 197

EP - 205

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 2

ER -